Page 22 Bain Capital Healthcare
P. 22
LIFE SCIENCES
Creating innovation…
At the core of the life
sciences ecosystem are the
biotechnology companies
developing the next
generation of therapies.
Our Life Sciences team partners with these product
companies to advance promising assets and
bring breakthrough medicines to patients. As a
leading investor in innovative drug development,
our team supports management through critical
decisions spanning leadership, clinical strategy,
manufacturing, and commercialization. With a
strong track record in new company formation
and strategic carve-outs, we help build enduring
businesses that translate scientific discovery into
meaningful patient impact.
22
Tanabe Pharma, a historic pharmaceutical
company based in Osaka, has a rich legacy
in developing therapies for CNS disorders,
immunology, diabetes, metabolic disease,
and vaccines. Following our carve-out and
acquisition, the company is accelerating growth
through strengthened R&D, external licensing,
and strategic acquisitions. Our investment
supports Tanabe’s transformation into a global
pharma platform, combining its scientific
heritage with Bain Capital’s life sciences
expertise to bring meaningful treatments to
patients worldwide.
Kailera Therapeutics is a clinical-stage
biopharmaceutical company developing next-
generation injectable and oral therapies for
obesity and related metabolic diseases. Its
lead program, KAI-9531, a GLP-1/GIP receptor
dual agonist, has shown strong Phase 2 results
and anchors a growing pipeline of high-quality
treatments for chronic weight management.
Our investment supports Kailera’s mission to
address the global obesity epidemic through
scientifically differentiated therapies that
improve health and quality of life.
Immunology Platform
Immunology Platform is a biopharmaceutical
company developing novel therapies for
autoimmune diseases with significant unmet
needs. Formed through a partnership between
Bain Capital and Bristol Myers Squibb, the
company launched with a diversified portfolio
of five clinical-stage immunology assets. Our
investment advances the new company's
mission to deliver transformative, immune-
restoring therapies that improve patient
outcomes worldwide.
Creating innovation…
At the core of the life
sciences ecosystem are the
biotechnology companies
developing the next
generation of therapies.
Our Life Sciences team partners with these product
companies to advance promising assets and
bring breakthrough medicines to patients. As a
leading investor in innovative drug development,
our team supports management through critical
decisions spanning leadership, clinical strategy,
manufacturing, and commercialization. With a
strong track record in new company formation
and strategic carve-outs, we help build enduring
businesses that translate scientific discovery into
meaningful patient impact.
22
Tanabe Pharma, a historic pharmaceutical
company based in Osaka, has a rich legacy
in developing therapies for CNS disorders,
immunology, diabetes, metabolic disease,
and vaccines. Following our carve-out and
acquisition, the company is accelerating growth
through strengthened R&D, external licensing,
and strategic acquisitions. Our investment
supports Tanabe’s transformation into a global
pharma platform, combining its scientific
heritage with Bain Capital’s life sciences
expertise to bring meaningful treatments to
patients worldwide.
Kailera Therapeutics is a clinical-stage
biopharmaceutical company developing next-
generation injectable and oral therapies for
obesity and related metabolic diseases. Its
lead program, KAI-9531, a GLP-1/GIP receptor
dual agonist, has shown strong Phase 2 results
and anchors a growing pipeline of high-quality
treatments for chronic weight management.
Our investment supports Kailera’s mission to
address the global obesity epidemic through
scientifically differentiated therapies that
improve health and quality of life.
Immunology Platform
Immunology Platform is a biopharmaceutical
company developing novel therapies for
autoimmune diseases with significant unmet
needs. Formed through a partnership between
Bain Capital and Bristol Myers Squibb, the
company launched with a diversified portfolio
of five clinical-stage immunology assets. Our
investment advances the new company's
mission to deliver transformative, immune-
restoring therapies that improve patient
outcomes worldwide.
